Navigation Links
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
Date:4/27/2011

ct candidates and research and clinical programs now underway or planned, the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize its product and drug candidates, competing drugs that may be superior to Regeneron's product and drug candidates, uncertainty of market acceptance of Regeneron's product and drug candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any license or collaboration agreement, including Regeneron's agreements with the sanofi-aventis Group and Bayer HealthCare, to be canceled or terminated without any product success, and risks associated with third party intellectual property and pending or future litigation relating thereto.  A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2010.  Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise, unless required by law.

Bayer Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management.  Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here.  These factors include those discussed in Bayer's public reports which are available on the Bayer website at '/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
2. Regeneron Announces Presentation at the 10th Annual Needham Healthcare Conference
3. Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
4. Regeneron Announces March 2011 Investor Conference Presentations
5. Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration
6. Regeneron Reports Full Year and Fourth Quarter 2010 Financial and Operating Results
7. Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET
8. Regeneron Announces Presentation at the ISI Annual Conference
9. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
10. Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME)
11. Christine A. Poon Elected to Regeneron Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014  Uroplasty, Inc. (NASDAQ: UPI ... and markets innovative proprietary products to treat voiding ... 2015 first quarter ended June 30, 2014.  ... Neuromodulation System grew 19% to $4.1 million, as ... of the prior year.  Total revenue for the ...
(Date:7/24/2014)... Ohio, July 24, 2014  Mettler-Toledo International Inc. (NYSE: ... for 2014.  Provided below are the highlights: ... the quarter compared with the prior year. Reported sales ... , Net earnings per diluted share as reported ... quarter of 2013. Adjusted EPS was $2.57, an increase ...
(Date:7/24/2014)... THOUSAND OAKS, Calif. , July 24, 2014 ... will report its second quarter financial results on Tuesday, July ... The announcement will be followed by a conference call with ... call from Amgen will be Robert A. Bradway , ... senior management team. Live audio of the conference ...
Breaking Medicine Technology:Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14Amgen Announces Webcast of 2014 Second Quarter Financial Results 2
... Facility, VIENNA, Va., Aug. 14 CEL-SCI CORPORATION,(Amex: ... into an agreement with a,biomedical real estate group under ... facility for its cancer drug Multikine(R). The,financial value of ... is located near Baltimore, Maryland. Once fully built out ...
... ALTO, Calif., Aug. 15 CV Therapeutics,Inc. (Nasdaq: ... developed jointly,by the American College of Cardiology Foundation ... week,s issue of Circulation, state that,"ranolazine may be ... Ranexa(R) (ranolazine extended-release tablets) is indicated for the,treatment ...
Cached Medicine Technology:CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug 2CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug 3CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug 4Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI) 2
(Date:7/24/2014)... Researchers at Le Bonheur Children,s Hospital and the ... a clinical trial of a new drug shown to ... healthy adult volunteers intranasally infected with respiratory syncytial virus ... respiratory tract infections in young children in the United ... the labs of Infectious Disease Specialist John DeVincenzo, MD. ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Memantine was initially ... first marketed in Germany under the brand name Akatinol; it ... nations as Ebixa and in the USA to Forest Labs ... 420 million in 2013. In the US, Forest reported Namenda ... protection expiry in Canada, Australia and the European region has ...
(Date:7/24/2014)... 24, 2014 As the age of ... egg freezing as a way to ensure future family ... decline with advancing reproductive age. Vitrification technology, a fast ... edge medical technology that allows a woman to have ... fertility years, which are then stored for future use. ...
(Date:7/24/2014)... scientists at Carnegie Mellon University, working with high-throughput ... Berkeley National Laboratory, have devised a computational method ... normal breast cells turn malignant and as they ... for analyzing how genes interact with each other ... published today by the online journal PLOS ...
(Date:7/24/2014)... In a recent report by CBS News, the ... end to criminal penalties associated with possession of small amounts ... reform in Washington DC, giving it one of the most ... penalties for possession of one ounce of marijuana or less ... more than an ounce of marijuana remain criminal offenses under ...
Breaking Medicine News(10 mins):Health News:RSV research breakthrough to help infected children 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 3Health News:Expanded Financial Options for Women Interested in Proactive Egg Freezing at Shady Grove Fertility 2Health News:Expanded Financial Options for Women Interested in Proactive Egg Freezing at Shady Grove Fertility 3Health News:Expanded Financial Options for Women Interested in Proactive Egg Freezing at Shady Grove Fertility 4Health News:Gene changes in breast cancer cells pinpointed with new computational method 2Health News:Gene changes in breast cancer cells pinpointed with new computational method 3Health News:Washington D.C. Decriminalizes Marijuana 2
... Steven Reinberg HealthDay Reporter , THURSDAY, Nov. ... medications can help people with heart disease live ... according to new guidelines from the American College of ... Following the updated recommendations can also improve quality of ...
... have found important new relationships between obesity, sleep-disordered ... children. "The intricate interdependencies between BMI, ... of particular importance in children, as their brains ... Spruyt, PhD, assistant professor in the Department of ...
... Nancy Grace and her partner danced a lively rumba to Spandau ... more was going on in the legal commentator,s brain than worry ... millions of neurons were hard at work doing what they apparently ... MacManus,s movements to create a pas de deux that had the ...
... , THURSDAY, Nov. 3 (HealthDay News) -- Smokers are more ... area of their brain that processes emotions was damaged by ... people who planned to stop smoking before they had a ... than those who hadn,t thought about quitting. These findings ...
... has long been known that cancer cells use nutrients differently ... field of cancer metabolism has shed new light on the ... demonstrating that manipulation of an enzyme called PKM2 is important ... by a scientific team at Beth Israel Deaconess Medical Center ...
... to stay awake. Very bright light not only arouses us ... can make us sleepy. It,s the reason some people use ... sleep. Now researchers at UCLA have identified ... or not. Jerome Siegel, a professor of psychiatry at ...
Cached Medicine News:Health News:Rx for Heart Patients: Healthier Living, Medication 2Health News:Rx for Heart Patients: Healthier Living, Medication 3Health News:Body weight, sleep-disordered breathing and cognition linked in children 2Health News:It takes two: Brains come wired for cooperation, neuroscientist asserts 2Health News:Some Smokers More Likely to Quit After Stroke Than Others 2Health News:Study identifies an expanded role for PKM2 in helping cancer cells survive 2Health News:Study identifies an expanded role for PKM2 in helping cancer cells survive 3Health News:UCLA researchers identify brain cells responsible for keeping us awake 2
New!...
... Electrical I/A unit for planned ... aspiration (foot control). Independent irrigation, suction, ... allows the surgeon to control all ... all functions simultaneously. Preset and actual ...
... Anterior and Posterior segment surgeries Vitrectomy-Lensectomy ... Ventury or Peristaltic Linear Aspiration. Interchangeable ... specific cutting action. Easy to read ... Cutting speed-variable from 1- 600 cuts ...
...
Medicine Products: